Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 1 mg in Patients With Type 2 Diabetes Mellitus.

NCT00252876 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00252876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00252876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 1 mg in Patients With Type 2 Diabetes Mellitus.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2005
Completion date
January 31, 2007
Enrollment
2,000
Sites
277

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes